HSA
ADMA icon

Hussman Strategic Advisors’s ADMA Biologics ADMA Stock Holding History

Hussman Strategic Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-63,000
Closed -$1.15M – 271
2025
Q2 		$1.15M Sell
63,000
-42,000
-40% -$856K 0.26% 132
2025
Q1 		$2.08M Buy
+105,000
New +$1.82M 0.5% 77
2021
Q1 		– Sell
-82,000
Closed -$160K – 326
2020
Q4 		$160K Sell
82,000
-18,000
-18% -$37.8K 0.04% 258
2020
Q3 		$239K Buy
+100,000
New +$274K 0.06% 246

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.82B AUM 73.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Hussman Strategic Advisors's ADMA Position: Q3 2025 in Review

Hussman Strategic Advisors sold out of ADMA Biologics (ADMA) in Q3 2025, closing a stake of 63,000 shares — an estimated $1.15M sold.

Hussman Strategic Advisors first reported a position in ADMA in Q3 2020 and held it in 4 quarters. The position peaked at $2.08M in Q1 2025. 365 funds tracked by Wall St. Rank hold ADMA as of Q3 2025.

  • Hussman Strategic Advisors reported no remaining ADMA Biologics position as of Q3 2025 after selling out during the quarter.
  • Hussman Strategic Advisors sold 63,000 ADMA Biologics shares in Q3 2025, an estimated $1.15M.
  • Hussman Strategic Advisors first reported a position in ADMA Biologics in Q3 2020 and held it in 4 quarters.
  • Hussman Strategic Advisors's ADMA Biologics position peaked at $2.08M in Q1 2025.
  • 365 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2025.

Based on Hussman Strategic Advisors's 13F filing for Q3 2025, filed 3 Nov 2025.